Business

Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth from Bespak and £79 million in revenues from CDMO Aesica, which Consort acquired in November 2014. The company attributes good part of Bespak's revenue growth … [Read more...] about Consort Medical revenue up 85%

Pulmatrix has issued a series of announcements regarding financing and its trading status on the NASDAQ exchange, a development deal for its PUR0200 inhaled COPD drug, and a new DPI it is developing, using its iSPERSE dry powder technology, for the treatment of pulmonary fungal infections in cystic fibrosis patients. Earlier this year, the company announced that it … [Read more...] about Pulmatrix announces financing, development deal with Mylan, new lead candidate

Milestone Pharmaceuticals has raised $17 million in a Series B financing round, the company said. According to the company, it will use the money for Phase 2 clinical development of MSP-2017, its intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). In November 2014, Milestone announced positive Phase 1 results … [Read more...] about Milestone raises $17 million for Phase 2 development of intranasal calcium channel antagonist

Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two companies signed an agreement at CPhI Russia 2015, which took place in April. According to the company's web site, Nativa … [Read more...] about VARI partners with Nativa on MDIs

Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline's Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in 125/25 mcg and 250/25 mcg versions, is manufactured by 3M Drug Delivery Systems. Mylan President Rajiv Malik … [Read more...] about Mylan launches Sirdupla salmeterol/fluticasone MDI in the UK

PARI Respiratory Equipment has announced that its Kitabis Pak, tobramycin inhalation solution packaged with a PARI LC Plus nebulizer for the treatment of cystic fibrosis, has won a 2015 American Package Design Award, presented by Graphic Design USA. The FDA approved Kitabis Pak in December 2014 and rated the product as a therapeutic equivalent of TOBI in March … [Read more...] about Kitabis Pak wins American Package Design Award

The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory infections in cancer patients whose immune systems have been compromised, the company has announced. In 2012, Pulmotect received a a $7.1 million … [Read more...] about Pulmotect gets $3 million grant for development of inhaled therapy for respiratory infections in cancer patients

Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex's RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher dosage levels for the treatment of conditions such as prostate cancer and endometriosis; NHT is … [Read more...] about Generex to co-develop buccal aerosol formulation of leuprolide for NHTherapeutics

Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the company obtained a GMP certificate to allow it to manufacture its own clinical trial supplies and has initiated a Phase 1 clinical trial of its Molgradex … [Read more...] about Inhaled drug developer Serendex says that it is prepared for clinical trials